US SEC Trading Suspension Halt Orders — July 10, 2026

Received Nasdaq deficiency notice for stockholders' equity <$2.5M; 45-day window to submit compliance plan (deadline Aug 21, 2026). Failure could lead to delisting.

Bid price below $1.00 for 30 consecutive days; ineligible for 180-day cure due to prior reverse split (Aug 12, 2025). Hearing request is the only stay.

Already on second 180-day extension (until Jan 4, 2027) after failing first cure period; cumulative non-compliance since Nov 14, 2025 signals structural price weakness.

Received first bid price deficiency notice; has full 180-day cure period, lowest immediate delisting risk among the four. [NEUTRAL/BEARISH]

Zero insider buying disclosed in any filing; management teams are not signaling confidence through open-market purchases.

No forward-looking guidance, capital allocation plans, or financial period comparisons were provided in any filing, indicating a lack of proactive investor communication.

Prior reverse stock split (1-for-10) failed to sustain bid price above $1.00 for even one year, suggesting structural price weakness and potential equity overhang.

Second compliance notice within 8 months (initial non-compliance Nov 14, 2025) shows persistent inability to maintain minimum bid price, raising risk of eventual delisting.

Failed all three alternative compliance measures (equity, market value, net income), indicating broad financial distress beyond just stock price.

Only company with a full 180-day cure period and no prior violations, making it the least severe but still a material risk. [NEUTRAL/BEARISH]

Ineligible for standard 180-day cure due to prior reverse split; hearing request is the only stay, with no assurance of success.

Failed all three compliance alternatives (equity, market value, net income), signaling broad financial distress beyond price.

Second non-compliance notice within 8 months; cumulative non-compliance since Nov 14, 2025, shows structural price weakness.

Zero insider purchases disclosed in any filing, indicating management lacks confidence in near-term recovery.

None provided financial outlook, capital allocation plans, or operational metrics, leaving investors without a recovery roadmap.

Second 180-day extension (until Jan 4, 2027) suggests the company is relying on time rather than fundamentals to cure.

Must submit compliance plan by Aug 21, 2026; if rejected, delisting process begins immediately with no guaranteed hearing stay.

1-for-10 reverse split in Aug 2025 failed to maintain compliance for even 12 months, indicating severe structural price weakness.

No disclosed plan to regain compliance beyond 'monitoring' stock price, leaving investors without a clear path to resolution.

All filings dated July 9-10, 2026, suggesting a potential Nasdaq compliance review sweep that could trigger further delisting notices across the micro-cap universe.

Full 180-day compliance period (until ~Jan 2027) provides the longest runway; if company announces buyback or reverse split, stock could rally toward $1.00.

Must submit compliance plan by Aug 21, 2026; a credible plan with equity infusion or reverse split could trigger a short-term rally.

Second extension until Jan 4, 2027, gives 6 months for operational improvements or strategic alternatives; potential for turnaround if fundamentals improve.

Requesting a hearing stays delisting; if Panel grants additional time, stock could see a relief rally from oversold levels.

Low-float micro-caps with high short interest could see sharp rallies on any positive compliance news (e.g., reverse split announcement, equity raise).

As the only company with potential financial flexibility (no equity deficiency disclosed), a share buyback could quickly boost bid price above $1.00.

If company announces reverse split to boost price above $1.00, pre-split buying could generate short-term gains despite long-term dilution risk.

Nasdaq granting a second extension suggests the exchange sees a plausible path to compliance; could indicate behind-the-scenes progress.

4 companies filed delisting-risk 8-Ks on the same day (July 9-10, 2026), suggesting a coordinated Nasdaq compliance review or broader market selloff in sub-$1.00 stocks.

3 of 4 filings (75%) involve minimum bid price violations, indicating that low stock price is the primary delisting risk for micro-caps, not financial insolvency.

NanoVibronix's failed reverse split (Aug 2025) highlights that reverse splits often provide only temporary relief, with many stocks re-violating within 12 months.

Zero insider buying across all four filings, contrasting with typical insider purchases during distress to signal confidence; management teams are not backing their own stocks.

None of the four companies provided any forward-looking statements, capital allocation plans, or operational updates, suggesting a reactive rather than proactive approach to compliance.

All 8-Ks filed within 24 hours (July 9-10, 2026) may indicate a Nasdaq compliance review cycle, potentially signaling more delisting notices to come in the micro-cap space.

Must submit plan by Aug 21, 2026; watch for plan details, potential reverse split, or equity infusion announcement. [Date: Aug 21, 2026]

Requested hearing to appeal delisting; watch for hearing date announcement and Panel decision, which will determine stock's fate. [Date: TBD]

Second 180-day extension ends Jan 4, 2027; monitor for reverse split or other compliance actions in Q4 2026. [Date: Jan 4, 2027]

Monitor daily closing bid price; 10 consecutive days above $1.00 needed to regain compliance. [Date: Ongoing]

Watch for Form 4 filings; insider buying would be a strong positive signal, while continued selling would confirm distress. [Date: Ongoing]

Watch for more 8-K filings from other micro-caps in coming weeks, as July 9-10 cluster suggests a compliance review wave. [Date: Ongoing]

Panel outcome will determine if stock remains listed; denial would trigger immediate delisting. [Date: TBD]

Next earnings report may provide operational update and compliance strategy; watch for any guidance on buybacks or reverse split. [Date: ~Oct 2026]